Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical pharmacology and therapy

• Publication date

  2015-01-01

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1002/cpt.7PMID 25670382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Translation of Anticancer Efficacy From Nonclinical Models to the Clinic

  2014cited by this paper
• Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib)

  2014cited by this paper
• Population pharmacokinetics and pharmacodynamics of BYL719, a phosphoinositide 3-kinase antagonist, in adult patients with advanced solid malignancies.

  2014cited by this paper
• Exposure–Response Relationship of T‐DM1: Insight Into Dose Optimization for Patients With HER2‐Positive Metastatic Breast Cancer

  2014cited by this paper
• The Scientific Basis of Body Surface Area–Based Dosing

  2014cited by this paper
• Evaluation of Tumor Size Response Metrics to Predict Survival in Oncology Clinical Trials

  2014cited by this paper
• A Review of Mixed-Effects Models of Tumor Growth and Effects of Anticancer Drug Treatment Used in Population Analysis

  2014cited by this paper
• Clinical development success rates for investigational drugs

  2014cited by this paper
• A General Network Pharmacodynamic Model–Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway

  2014cited by this paper
• Conventional Dosing of Anticancer Agents: Precisely Wrong or Just Inaccurate?

  2014cited by this paper
• Semi-Mechanistic Pharmacokinetic/Pharmacodynamic Modeling of the Antitumor Activity of LY2835219, a New Cyclin-Dependent Kinase 4/6 Inhibitor, in Mice Bearing Human Tumor Xenografts

  2014cited by this paper
• Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).

  2014cited by this paper
• Exploratory Modeling and Simulation to Support Development of Motesanib in Asian Patients With Non–Small Cell Lung Cancer Based on MONET1 Study Results

  2014cited by this paper
• Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.

  2014influential reference
• Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

  2013cited by this paper
• Model-Based Approach to Describe G-CSF Effects in Carboplatin-Treated Cancer Patients

  2013cited by this paper
• Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

  2013cited by this paper
• Evaluation of Progression-Free Survival as a Surrogate Endpoint for Survival in Chemotherapy and Targeted Agent Metastatic Colorectal Cancer Trials

  2013cited by this paper
• PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST

  2013influential reference
• Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response

  2013cited by this paper
• PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

  2013influential reference
• A physiologically based pharmacokinetic (PBPK) approach to evaluate pharmacokinetics in patients with cancer

  2013cited by this paper
• Survival prediction in everolimus-treated patients with metastatic renal cell carcinoma incorporating tumor burden response in the RECORD-1 trial.

  2013cited by this paper
• Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer.

  2013cited by this paper
• The Combination of Exposure‐Response and Case‐Control Analyses in Regulatory Decision Making

  2013cited by this paper
• Time to tumor growth: a model end point and new metric system for oncology clinical trials.

  2013cited by this paper
• Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics.

  2012cited by this paper
• Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

  2012cited by this paper
• The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia

  2012cited by this paper
• Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin

  2012cited by this paper
• Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH‐Dependent Solubility the Achilles Heel of Targeted Therapy?

  2012cited by this paper
• Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth

  2012cited by this paper
• A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy

  2012cited by this paper
• Exposure–response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection

  2012cited by this paper
• Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

  2012cited by this paper
• The initial change in tumor size predicts response and survival in patients with metastatic colorectal cancer treated with combination chemotherapy.

  2012cited by this paper
• Progression-Free Survival as a Surrogate Endpoint for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis from 50 Randomized First-Line Trials

  2012cited by this paper
• Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

  2012cited by this paper
• Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development

  2012cited by this paper
• PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts

  2012cited by this paper
• Model-based treatment optimization of a novel VEGFR inhibitor.

  2012cited by this paper
• Drug interaction potential of trastuzumab emtansine (T-DM1) combined with pertuzumab in patients with HER2-positive metastatic breast cancer.

  2012cited by this paper
• Multiscale Kinetic Modeling of Liposomal Doxorubicin Delivery Quantifies the Role of Tumor and Drug-Specific Parameters in Local Delivery to Tumors

  2012cited by this paper
• Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

  2012cited by this paper
• Tumor Burden Modeling Versus Progression-Free Survival for Phase II Decision Making

  2012cited by this paper
• Estimation of renal cell carcinoma treatment effects from disease progression modeling

  2012cited by this paper
• Models of Excellence: Improving Oncology Drug Development

  2012cited by this paper
• Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000–2009

  2011cited by this paper
• Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review

  2011cited by this paper
• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  2011cited by this paper
• Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer

  2011cited by this paper
• Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

  2011cited by this paper
• Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development

  2010cited by this paper
• Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice

  2010cited by this paper
• Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

  2010cited by this paper
• Tumor Regression and Growth Rates Determined in Five Intramural NCI Prostate Cancer Trials: The Growth Rate Constant as an Indicator of Therapeutic Efficacy

  2010cited by this paper
• Model-based neutrophil-guided dose adaptation in chemotherapy: evaluation of predicted outcome with different types and amounts of information.

  2010cited by this paper
• Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model

  2010cited by this paper
• Prediction of Neutropenia‐Related Effects of a New Combination Therapy With the Anticancer Drugs BI 2536 (a Plk1 Inhibitor) and Pemetrexed

  2010influential reference
• Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies

  2010cited by this paper
• Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis

  2010cited by this paper
• A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development

  2010cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Elucidation of Relationship Between Tumor Size and Survival in Non‐Small‐Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development

  2009cited by this paper
• A tool for neutrophil guided dose adaptation in chemotherapy

  2009cited by this paper
• Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

  2009cited by this paper
• Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics.

  2009cited by this paper
• On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies

  2009cited by this paper
• Detecting an overall survival benefit that is derived from progression-free survival.

  2009cited by this paper
• A Dynamic Model of Hand‐and‐Foot Syndrome in Patients Receiving Capecitabine

  2009cited by this paper
• A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients With Relapsed or Refractory Non‐Hodgkin's or Hodgkin's Lymphoma

  2009cited by this paper
• Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies.

  2009cited by this paper
• Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

  2009cited by this paper
• Pharmacokinetic Considerations for New Targeted Therapies

  2009cited by this paper
• Advances in Cancer Therapeutics

  2009cited by this paper
• Direct In Vivo Xenograft Tumor Model for Predicting Chemotherapeutic Drug Response in Cancer Patients

  2009cited by this paper
• Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data.

  2008cited by this paper
• Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data.

  2008cited by this paper
• Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer

  2008cited by this paper
• Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors.

  2008cited by this paper
• Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents

  2008cited by this paper
• Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

  2008cited by this paper
• Model‐based Drug Development

  2007cited by this paper
• A Population Pharmacokinetic and Pharmacodynamic Evaluation of Pralatrexate in Patients with Hematologic Malignancies.

  2007cited by this paper
• Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

  2007cited by this paper
• Predicting the active doses in humans from animal studies: a novel approach in oncology.

  2007cited by this paper
• A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

  2006cited by this paper
• Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

  2004cited by this paper
• Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer

  2003cited by this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cited by this paper
• Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

  2002cited by this paper
• Model of chemotherapy-induced myelosuppression with parameter consistency across drugs.

  2002cited by this paper
• Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF

  1999cited by this paper

• A Systematic Comparative Analysis of Tumor Size Models Based on Erlotinib Clinical Data in Advanced NSCLC

  2025cites this paper
• Model-informed drug development of novel ROCK2 inhibitor TDI01: population pharmacokinetic study and simulation

  2025cites this paper
• Systems-level exploration of Withania somnifera-derived phytochemicals against breast cancer: A network pharmacology and molecular modeling approach

  2025cites this paper
• Translational Model‐Informed Dose Selection for Iruplinalkib, a Selective Oral ALK/ROS1 Tyrosine Kinase Inhibitor

  2025cites this paper
• Application of quantitative pharmacology analysis to support early clinical development of oncology drugs: dose selection

  2024cites this paper
• Translational Pharmacokinetic-Toxicodynamic Model of Myelosuppression for Dose Optimization in Combination Chemotherapy of Capecitabine and Oxaliplatin from Rats to Humans

  2024cites this paper
• Moving the needle for oncology dose optimization: A call for action

  2024cites this paper
• Moving the Needle for Oncology Dose Optimization: A Call for Action

  2024cites this paper
• Model‐informed Evidence for Clinical Non‐inferiority of Every‐2‐Weeks Versus Standard Weekly Dosing Schedule of Cetuximab in Metastatic Colorectal Cancer

  2024cites this paper
• Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2

  2023cites this paper
• Model‐based prediction of effective target exposure for MEN1611 in combination with trastuzumab in HER2‐positive advanced or metastatic breast cancer patients

  2023cites this paper
• C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework

  2023cites this paper
• Translational PK-PD/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule

  2023cites this paper
• Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations

  2022cites this paper
• Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma

  2022cites this paper
• Analysis of pharmacological data using mathematical modeling approach

  2022cites this paper
• Interspecies and in vitro‐in vivo scaling for quantitative modeling of whole‐body drug pharmacokinetics in patients: Application to the anticancer drug oxaliplatin

  2022cites this paper
• Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC

  2022cites this paper
• Pharmacodynamic Model-Based Safety Management of Eribulin-Induced Myelosuppression in Patients With Breast Cancer

  2022cites this paper
• Tumor growth inhibition modeling to support the starting dose for dacomitinib

  2022cites this paper
• Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition–overall survival modeling framework

  2021cites this paper
• NONCLINICAL, CLINICAL, AND MODEL‐INFORMED DRUG DEVELOPMENT

  2021cites this paper
• Systems Modeling to Quantify Safety Risks in Early Drug Development: Using Bifurcation Analysis and Agent-Based Modeling as Examples

  2021cites this paper
• Tumor growth inhibition modeling of individual lesion dynamics and interorgan variability in HER2‐negative breast cancer patients treated with docetaxel

  2021cites this paper
• Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates.

  2021cites this paper
• A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib

  2021cites this paper
• Quantification of Pharmacokinetic Profiles of PD-1/PD-L1 Antibodies by Validated ELISAs

  2020cites this paper
• The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib

  2020cites this paper
• Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors

  2020cites this paper
• Can quantitative pharmacology improve productivity in pharmaceutical research and development?

  2020cites this paper
• Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework

  2020cites this paper
• Efficacy and Safety Exposure–Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

  2020cites this paper
• Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens

  2020cites this paper
• Immune cells as tumor drug delivery vehicles.

  2020cites this paper
• Population Pharmacokinetics of Brigatinib in Healthy Volunteers and Patients With Cancer

  2020cites this paper
• Brigatinib Dose Rationale in Anaplastic Lymphoma Kinase–Positive Non‐Small Cell Lung Cancer: Exposure–Response Analyses of Pivotal ALTA Study

  2020cites this paper
• Population Pharmacokinetic Modeling and Exposure–Response Assessment for the Antibody‐Drug Conjugate Brentuximab Vedotin in Hodgkin's Lymphoma in the Phase III ECHELON‐1 Study

  2019cites this paper
• An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias

  2019cites this paper
• Dosage adjustments in pivotal clinical trials with oral targeted therapies in solid tumors conducted in Europe

  2019cites this paper
• Model-Informed Drug Development, Pharmacokinetic/Pharmacodynamic Cutoff Value Determination, and Antibacterial Efficacy of Benapenem against Enterobacteriaceae

  2019cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors

  2019cites this paper
• Population pharmacokinetics of pevonedistat alone or in combination with standard of care in patients with solid tumours or haematological malignancies

  2019cites this paper
• Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling

  2019cites this paper
• improved cancer drug development with drug disco

  2019cites this paper
• Quantitative Systems Pharmacology: An Exemplar Model‐Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

  2019cites this paper
• Application of PK-PD Modeling and Simulation Approaches for Immuno-Oncology Drugs

  2018cites this paper
• Understanding Hematological Toxicities Using Mathematical Modeling

  2018cites this paper
• Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study

  2018cites this paper
• Pharmacometric Applications and Challenges in the Development of Therapeutic Antibodies in Immuno-Oncology

  2018cites this paper
• Model‐Informed Reverse and Forward Translation of Safety Risks in Drug Development

  2018cites this paper
• Challenges and Opportunities in Dose Finding in Oncology and Immuno‐oncology

  2018cites this paper
• Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

  2018cites this paper
• Quantitative translational modeling to facilitate preclinical to clinical efficacy & toxicity translation in oncology

  2018cites this paper
• Human 3D Gastrointestinal Microtissue Barrier Function As a Predictor of Drug-Induced Diarrhea

  2018cites this paper
• Optimizing drug development in oncology by clinical trial simulation: Why and how?

  2017cites this paper
• A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

  2017cites this paper
• Exposure–Response Analysis of Necitumumab Efficacy in Squamous Non‐Small Cell Lung Cancer Patients

  2017cites this paper
• Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

  2017cites this paper
• Towards Quantitative Systems Pharmacology Models of Chemotherapy‐Induced Neutropenia

  2017cites this paper
• Translational Modeling of Drug‐Induced Myelosuppression and Effect of Pretreatment Myelosuppression for AZD5153, a Selective BRD4 Inhibitor

  2017cites this paper
• Exposure–Response of Veliparib to Inform Phase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

  2017cites this paper
• Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development

  2017cites this paper
• Translational learning from clinical studies predicts drug pharmacokinetics across patient populations

  2017cites this paper
• Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib‐Treated Patients With Gastrointestinal Stromal Tumors

  2017cites this paper
• Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study

  2017cites this paper
• Translational pharmacokinetic-pharmacodynamic analysis in the pharmaceutical industry: an IQ Consortium PK-PD Discussion Group perspective.

  2017cites this paper
• Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.

  2017cites this paper
• Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011–2017: Lessons Learned for Anticancer Drug Development

  2017cites this paper
• Systems Pharmacology Model of Gastrointestinal Damage Predicts Species Differences and Optimizes Clinical Dosing Schedules

  2017cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 243 Pharmacometrics to improve clinical benefit assessment in oncology

  2017cites this paper
• Enhancing value of clinical pharmacodynamics in oncology drug development: An alliance between quantitative pharmacology and translational science

  2017cites this paper
• Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies

  2017cites this paper
• Quantitative Evaluations of Time‐Course and Treatment Effects of Systemic Agents for Psoriasis: A Model‐Based Meta‐Analysis

  2017cites this paper
• Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients

  2017cites this paper
• Managing Innovation to Maximize Value Along the Discovery‐Translation‐Application Continuum

  2017cites this paper
• Exposure–ResponseofVeliparib to InformPhase II Trial Design in Refractory or Relapsed Patients with Hematological Malignancies

  2017cites this paper
• Quantitative Systems Pharmacology: A Case for Disease Models

  2016cites this paper
• Assessing interindividual variability by Bayesian-PBPK modeling

  2016cites this paper
• Modeling and simulation of maintenance treatment in first-line non-small cell lung cancer with external validation

  2016cites this paper
• Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy

  2016cites this paper
• New Approaches to Drug Discovery

  2016cites this paper
• Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics.

  2016cites this paper
• Title Computational neurorehabilitation : modeling plasticity and learning to predict recovery Permalink

  2016cites this paper
• Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab‐Treated Advanced Melanoma

  2016cites this paper
• Translational Medicine: Enabling the Proof of Concepts

  2016cites this paper
• Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.

  2016cites this paper
• Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline

  2016cites this paper
• Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles

  2016cites this paper
• Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success

  2016cites this paper
• A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use

  2015cites this paper
• Oncology trial design: More accurately and efficiently advancing the field

  2015cites this paper
• Clinical Pharmacology & Therapeutics: The Next Five Years

  2015cites this paper
• Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients

  2015cites this paper
• Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations

  2015cites this paper
• Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models

  2015cites this paper
• Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy

  2015cites this paper
• Digital Commons@Becker

  year unknowncites this paper